FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Irina Cleemput

Research Profile

Geographic Areas

Activities & Behaviors

Chemicals & Drugs

Orphan Drug Production

Procedures

Concepts & Ideas

Physiology

Decision Making

Disorders

Rare Diseases

Co-author Network

Publications

TOP 3
Irina Cleemput; Chris De Laet
Analysis of the costs of dialysis and the effects of an incentive mechanism for low-cost dialysis modalities.
Margreet Franken; Irina Cleemput; Maïté le Polain; Marc A Koopmanschap
Similarities and differences between five European drug reimbursement systems.
Irina Cleemput; Margreet Franken; Marc A Koopmanschap; Maïté le Polain
European drug reimbursement systems' legitimacy: five-country comparison and policy tool.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Irina Cleemput (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Irina Cleemput; Chris De Laet
Analysis of the costs of dialysis and the effects of an incentive mechanism for low-cost dialysis modalities.
Health policy (Amsterdam, Netherlands) 2013;110(2-3):172-9.
2012: Margreet Franken; Irina Cleemput; Maïté le Polain; Marc A Koopmanschap
Similarities and differences between five European drug reimbursement systems.
International journal of technology assessment in health care 2012;28(4):349-57.
2012: Irina Cleemput; Margreet Franken; Marc A Koopmanschap; Maïté le Polain
European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
International journal of technology assessment in health care 2012;28(4):358-66.
2012: Sophie Gerkens; Caroline Obyn; Stephan Devriese; Jeannine Gailly; Irina Cleemput
Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation.
Journal of thrombosis and thrombolysis 2012;34(3):300-9.
2012: Mattias Neyt; Nancy Thiry; Irina Cleemput; Chris De Laet
Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data.
Health policy (Amsterdam, Netherlands) 2012;106(2):207-10.
2011: Alain Denis; Christel Fostier; Frank Hulstaert; Lut Mergaert; Irina Cleemput; Steven Simoens
Critical assessment of belgian reimbursement dossiers of orphan drugs.
PharmacoEconomics 2011;29(10):883-93.
2011: Lieven Annemans; Irina Cleemput; Frank Hulstaert; Steven Simoens
Stimulating pharmaceutical innovation in the EU.
Expert review of pharmacoeconomics & outcomes research 2011;11(3):235-9.
2011: Lieven Annemans; Irina Cleemput; Frank Hulstaert; Steven Simoens
Valorising and creating access to innovative medicines in the European union.
Frontiers in pharmacology 2011;2():57.
2011: Irina Cleemput; Mattias Neyt; Nancy Thiry; Chris De Laet; Mark Leys
Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.
International journal of technology assessment in health care 2011;27(1):71-6.
2010: Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
A comparative study of European rare disease and orphan drug markets.
Health policy (Amsterdam, Netherlands) 2010;97(2-3):173-9.
2010: Iris Pasternack; Kristian Lampe; Chris de Laet; Irina Cleemput; Mattias Neyt; Claudia Wild; Finn Børlum Kristensen
Harmonizing HTA.
International journal of technology assessment in health care 2010;26(2):226-7.
2010: Irina Cleemput
A social preference valuations set for EQ-5D health states in Flanders, Belgium.
The European journal of health economics : HEPAC : health economics in prevention and care 2010;11(2):205-13.
2010: C Obyn; Irina Cleemput
The capital cost and productivity of MRI in a Belgian setting.
JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR) 2010;93(2):92-6.
2010: Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
Issues surrounding orphan disease and orphan drug policies in Europe.
Applied health economics and health policy 2010;8(5):343-50.
2010: Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.
Journal of medical economics 2010;13(2):295-301.
2009: Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
[Orphan diseases and orphan medicines: a Belgian and European study].
Journal de pharmacie de Belgique 2009;(4):131-7.
2009: Iris Pasternack; Heidi Anttila; Marjukka Mäkelä; Tuija Ikonen; Pirjo Räsänen; Kristian Lampe; Hans van Brabandt; Irina Cleemput; Chris de Laet; Marco Marchetti; Pietro Refolo; Dario Sacchini; Regina Kunz; Alain Nordmann; Dagmar Lühmann; Bo Freyschuss
Testing the HTA core model: experiences from two pilot projects.
International journal of technology assessment in health care 2009;25 Suppl 2():21-7.
2009: Irina Cleemput; Philippe Van Wilder
History of health technology assessment in Belgium.
International journal of technology assessment in health care 2009;25 Suppl 1():82-7.
2009: Irina Cleemput; Philippe van Wilder; Michel Huybrechts; France Vrijens
Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009;12(4):441-9.
2009: Nancy Thiry; Chris De Laet; Frank Hulstaert; Mattias Neyt; Michel Huybrechts; Irina Cleemput
Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
International journal of technology assessment in health care 2009;25(2):161-70.
2009: Irina Cleemput; Nancy Thiry
Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
PharmacoEconomics 2009;27(5):433; author reply 433-4.
2008: Sophie Gerkens; Ralph Crott; Irina Cleemput; Jean-Paul Thissen; Marie-Christine Closon; yves horsmans; Claire Beguin
Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity.
International journal of technology assessment in health care 2008;24(3):318-25.
2008: Irina Cleemput; Cécile Camberlin; Ann Van den Bruel; Dirk Ramaekers
Methodology for calculating a country's need for positron emission tomography scanners.
International journal of technology assessment in health care 2008;24(1):20-4.
2007: Annick Van den Bruel; Irina Cleemput; Bert Aertgeerts; Dirk Ramaekers; Frank Buntinx
The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed.
Journal of clinical epidemiology 2007;60(11):1116-22.
2007: Irina Cleemput; Fabienne Dobbels
Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date.
PharmacoEconomics 2007;25(4):269-86.
2006: Irina Cleemput; Mark Leys; Dirk Ramaekers; Luc Bonneux
Balancing evidence and public opinion in health technology assessments: the case of leukoreduction.
International journal of technology assessment in health care 2006;22(4):403-7.
2006: Ann Lecluyse; Irina Cleemput
Making health continuous: implications of different methods on the measurement of inequality.
Health economics 2006;15(1):99-104.
2005: Kris Denhaerynck; Fabienne Dobbels; Irina Cleemput; Ariane Desmyttere; Petra Schäfer-Keller; Stefan Schaub; Sabina De Geest
Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review.
Transplant international : official journal of the European Society for Organ Transplantation 2005;18(10):1121-33.
2005: Luc Bonneux; Irina Cleemput; Dirk Ramaekers
Protected carotid artery stenting (PCAS): a short medical technology assessment.
Acta chirurgica Belgica 2005;105(5):436-41.
2005: Lieven Annemans; Irina Cleemput; Mark Lamotte; Alan McNeill; Timothy Hargreave
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
BJU international 2005;96(4):566-71.
2005: Ariane Desmyttere; Fabienne Dobbels; Irina Cleemput; Sabina De Geest
Noncompliance with immunosuppressive regimen in organ transplantation: is it worth worrying about?
Acta gastro-enterologica Belgica 2005;68(3):347-52.
2004: Irina Cleemput; Paul Kind; Katrien Kesteloot
Re-scaling social preference data: implications for modelling.
The European journal of health economics : HEPAC : health economics in prevention and care 2004;5(4):290-8.
2004: Irina Cleemput; Katrien Kesteloot; Philip Moons; Yves Vanrenterghem; Johannes P van Hooff; Jean-Paul Squifflet; Sabina De Geest
The construct and concurrent validity of the EQ-5D in a renal transplant population.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2004;7(4):499-509.
2004: Irina Cleemput; Katrien Kesteloot; Yves Vanrenterghem; Sabina De Geest
The economic implications of non-adherence after renal transplantation.
PharmacoEconomics 2004;22(18):1217-34.
2003: Irina Cleemput; Katrien Kesteloot; Sabina De Geest; Fabienne Dobbels; Yves Vanrenterghem
Health professionals' perceptions of health status after renal transplantation: a comparison with transplantation candidates' expectations.
Transplantation 2003;76(1):176-82.
2002: Irina Cleemput; Katrien Kesteloot
Economic implications of non-compliance in health care.
Lancet 2002;359(9324):2129-30.
2002: Irina Cleemput; Katrien Kesteloot; Sabina DeGeest
A review of the literature on the economics of noncompliance. Room for methodological improvement.
Health policy (Amsterdam, Netherlands) 2002;59(1):65-94.
2001: Fabienne Dobbels; Sabina De Geest; Irina Cleemput; B Fischler; Katrien Kesteloot; Johan Vanhaecke; Yves Vanrenterghem
Psychosocial and behavioral selection criteria for solid organ transplantation.
Progress in transplantation (Aliso Viejo, Calif.) 2001;11(2):121-30; quiz 131-2.
2000: Irina Cleemput; Katrien Kesteloot
Health technology assessment in Belgium.
International journal of technology assessment in health care 2000;16(2):325-46.
2000: E van der Schueren; Katrien Kesteloot; Irina Cleemput
Federation of European Cancer Societies. Full report. Economic evaluation in cancer care: questions and answers on how to alleviate conflicts between rising needs and expectations and tightening budgets.
European journal of cancer (Oxford, England : 1990) 2000;36(1):13-36.